269 related articles for article (PubMed ID: 19738905)
1. The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.
Sørensen RB; Berge-Hansen L; Junker N; Hansen CA; Hadrup SR; Schumacher TN; Svane IM; Becker JC; thor Straten P; Andersen MH
PLoS One; 2009 Sep; 4(9):e6910. PubMed ID: 19738905
[TBL] [Abstract][Full Text] [Related]
2. Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase.
Munir S; Larsen SK; Iversen TZ; Donia M; Klausen TW; Svane IM; Straten PT; Andersen MH
PLoS One; 2012; 7(4):e34568. PubMed ID: 22539948
[TBL] [Abstract][Full Text] [Related]
3. The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase.
Andersen MH
Cancer Immunol Immunother; 2012 Aug; 61(8):1289-97. PubMed ID: 22388712
[TBL] [Abstract][Full Text] [Related]
4. Glycogen Synthase Kinase-3β (GSK-3β) Inhibition Enhances Dendritic Cell-based Cancer Vaccine Potency via Suppression of Interferon-γ-induced Indoleamine 2,3-Dioxygenase Expression.
Noh KT; Son KH; Jung ID; Kang TH; Choi CH; Park YM
J Biol Chem; 2015 May; 290(19):12394-402. PubMed ID: 25814664
[TBL] [Abstract][Full Text] [Related]
5. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
6. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.
Sørensen RB; Hadrup SR; Svane IM; Hjortsø MC; Thor Straten P; Andersen MH
Blood; 2011 Feb; 117(7):2200-10. PubMed ID: 21079151
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT.
Ou X; Cai S; Liu P; Zeng J; He Y; Wu X; Du J
J Cancer Res Clin Oncol; 2008 May; 134(5):525-33. PubMed ID: 17909857
[TBL] [Abstract][Full Text] [Related]
8. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells.
Boasso A; Herbeuval JP; Hardy AW; Winkler C; Shearer GM
Blood; 2005 Feb; 105(4):1574-81. PubMed ID: 15466932
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy.
Su Q; Wang C; Song H; Zhang C; Liu J; Huang P; Zhang Y; Zhang J; Wang W
J Mater Chem B; 2021 May; 9(18):3892-3899. PubMed ID: 33928989
[TBL] [Abstract][Full Text] [Related]
10. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.
Katz JB; Muller AJ; Prendergast GC
Immunol Rev; 2008 Apr; 222():206-21. PubMed ID: 18364004
[TBL] [Abstract][Full Text] [Related]
11. Neem leaf glycoprotein overcomes indoleamine 2,3 dioxygenase mediated tolerance in dendritic cells by attenuating hyperactive regulatory T cells in cervical cancer stage IIIB patients.
Roy S; Barik S; Banerjee S; Bhuniya A; Pal S; Basu P; Biswas J; Goswami S; Chakraborty T; Bose A; Baral R
Hum Immunol; 2013 Aug; 74(8):1015-23. PubMed ID: 23628394
[TBL] [Abstract][Full Text] [Related]
12. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.
Avril T; Saikali S; Vauleon E; Jary A; Hamlat A; De Tayrac M; Mosser J; Quillien V
J Neuroimmunol; 2010 Aug; 225(1-2):22-33. PubMed ID: 20493562
[TBL] [Abstract][Full Text] [Related]
13. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
[TBL] [Abstract][Full Text] [Related]
14. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.
Sharma MD; Baban B; Chandler P; Hou DY; Singh N; Yagita H; Azuma M; Blazar BR; Mellor AL; Munn DH
J Clin Invest; 2007 Sep; 117(9):2570-82. PubMed ID: 17710230
[TBL] [Abstract][Full Text] [Related]
15. Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy.
Zahm CD; Johnson LE; McNeel DG
Cancer Immunol Immunother; 2019 Oct; 68(10):1661-1669. PubMed ID: 31606777
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.
Munn DH
Curr Opin Immunol; 2006 Apr; 18(2):220-5. PubMed ID: 16460921
[TBL] [Abstract][Full Text] [Related]
17. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
18. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model.
Zheng X; Koropatnick J; Chen D; Velenosi T; Ling H; Zhang X; Jiang N; Navarro B; Ichim TE; Urquhart B; Min W
Int J Cancer; 2013 Feb; 132(4):967-77. PubMed ID: 22870862
[TBL] [Abstract][Full Text] [Related]
19. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
[TBL] [Abstract][Full Text] [Related]
20. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
Han Y; Chen Z; Yang Y; Jiang Z; Gu Y; Liu Y; Lin C; Pan Z; Yu Y; Jiang M; Zhou W; Cao X
Hepatology; 2014 Feb; 59(2):567-79. PubMed ID: 23960017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]